Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone 2015-2016 Formulations
NCT02563093Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated), Fluzone Intradermal, trivalent inactivated influenza vaccine high-dose in influenza, sponsored by Sanofi. Started Sep 2015; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)Fluzone Intradermaltrivalent inactivated influenza vaccine high-dose
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02563093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563093.